SB012 for Treatment of Active Ulcerative Colitis: Prospective Multi-centre Randomised Double-blind Placebo-controlled Phase IIa Clinical Trial to Evaluate Efficacy, Pharmacokinetics, Tolerability and Safety of SB012 Enema Administered OD
Phase of Trial: Phase I/II
Latest Information Update: 18 Jan 2017
At a glance
- Drugs Anti-GATA3 gene-therapy (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms SECURE
- Sponsors sterna biologicals
- 07 Jun 2017 Biomarkers information updated
- 12 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
- 12 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Apr 2017.